| Literature DB >> 29209832 |
Maarten F J Seesing1, Lucas Goense1, Jelle P Ruurda1, Misha D P Luyer2, Grard A P Nieuwenhuijzen2, Richard van Hillegersberg3,4.
Abstract
BACKGROUND: The preferred surgical approach for esophageal cancer is a minimally invasive transthoracic esophagectomy with a two-field lymph node dissection. The thoracoscopic phase may be performed either in prone- or in left lateral decubitus (LLD) position. Prone positioning has been associated with better pulmonary outcomes compared to LLD positioning; however, conversion to a classic thoracotomy is more difficult. The semiprone position has been proposed as an alternative approach.Entities:
Keywords: Minimally invasive esophagectomy; Prone position; Semiprone position
Mesh:
Year: 2017 PMID: 29209832 PMCID: PMC5956092 DOI: 10.1007/s00464-017-5975-1
Source DB: PubMed Journal: Surg Endosc ISSN: 0930-2794 Impact factor: 4.584
Fig. 1A Patient positioned in semiprone position. B Trocar placement in the semiprone position. Robotic arms 1 (A) and 2 (B) camera (C), and two assisting ports (D, E)
Fig. 2A Patient positioned in prone position. B Trocar placement in the prone position. A camera port (A), two 12-mm ports (B, C), and a 5-mm port (D)
Patient and treatment-related characteristics in relation to surgical procedure
| Characteristic | Before matching | After matching | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Semiprone ( | Prone ( |
| Semiprone ( | Prone ( |
| |||||
|
|
|
|
| |||||||
| Gender | ||||||||||
| Female | 31 | 37.8% | 10 | 26% | 0.649 | 13 | 33% | 10 | 26% | 0.456 |
| Male | 51 | 62.2% | 29 | 74% | 26 | 67% | 29 | 74% | ||
| Age (years) | 62 | ± 8.68 | 63 | ± 8.93 | 0.186 | 63 | ± 25.33 | 63 | ± 8.93 | 0.492 |
| BMI (kg/m2)a | 24.95 | ± 4.36 | 24.55 | ± 4.5 | 0.515 | 25.34 | ± 4.86 | 24.55 | ± 4.5 | 0.478 |
| ASA score | ||||||||||
| I | 22 | 27% | 1 | 2% | 0.004 | 6 | 15% | 1 | 2% | 0.140 |
| II | 49 | 60% | 28 | 72% | 24 | 62% | 28 | 72% | ||
| III | 11 | 13% | 10 | 26% | 9 | 23% | 10 | 26% | ||
| COPD | ||||||||||
| No | 69 | 84.1% | 35 | 90% | 0.408 | 33 | 85% | 35 | 90% | 0.498 |
| Yes | 13 | 15.9% | 4 | 10% | 6 | 15% | 4 | 10% | ||
| Cardiac comorbidity | ||||||||||
| No | 61 | 74.4% | 34 | 87% | 0.109 | 34 | 87% | 34 | 87% | 1.000 |
| Yes | 21 | 25.6% | 5 | 13% | 5 | 13% | 5 | 13% | ||
| Diabetes mellitus | ||||||||||
| No | 75 | 91.5% | 35 | 90% | 0.758 | 37 | 95% | 35 | 90% | 0.395 |
| Yes | 7 | 8.5% | 4 | 10% | 2 | 5% | 4 | 10% | ||
| Smoking | ||||||||||
| No | 29 | 35.4% | 23 | 59% | < 0.001 | 19 | 49% | 23 | 59% | 0.364 |
| Yes | 53 | 64.6% | 16 | 41% | 20 | 51% | 16 | 41% | ||
| Alcohol | ||||||||||
| No | 25 | 30.5% | 17 | 44% | 0.174 | 13 | 33% | 17 | 44% | 0.532 |
| Yes | 53 | 64.6% | 22 | 46% | 26 | 67% | 22 | 46% | ||
| cT stage | ||||||||||
| T1,2 | 24 | 29% | 8 | 21% | 0.307 | 10 | 26% | 8 | 21% | 0.591 |
| T3,4 | 58 | 71% | 31 | 79% | 29 | 74% | 31 | 79% | ||
| cN stage | ||||||||||
| N0 | 26 | 32% | 8 | 21% | 0.200 | 10 | 26% | 8 | 21% | 0.591 |
| N+ | 56 | 58% | 31 | 79% | 29 | 74% | 31 | 79% | ||
| Histology | ||||||||||
| ADC | 43 | 53% | 21 | 54% | 0.938 | 23 | 59% | 21 | 54% | 0.648 |
| SCC | 39 | 47% | 18 | 46% | 16 | 41% | 18 | 46% | ||
| Tumor location | ||||||||||
| Proximal | 6 | 7% | 0 | 0% | 0.093 | 2 | 5% | 0 | 0% | 0.108 |
| Middle | 22 | 27% | 16 | 41% | 9 | 23% | 16 | 41% | ||
| Distal | 54 | 66% | 23 | 59% | 28 | 72% | 23 | 59% | ||
| nCRT | ||||||||||
| No | 30 | 36.6% | 3 | 8% | 0.001 | 7 | 20% | 3 | 8% | 0.176 |
| Yes | 52 | 63.4% | 36 | 92% | 32 | 80% | 36 | 92% | ||
Data are expressed as N (%) or mean ± SD. Neoadjuvant chemoradiotherapy consisted of intravenous carboplatin [AUC 2 mg/mL/min] and intravenous paclitaxel (50 mg/m2 of body-surface area) for 23 days with concurrent radiotherapy (41·4 Gy, given in 23 fractions of 1·8 Gy on 5 days/week)
BMI body mass index, ASA American Society of Anesthesiologists, COPD chronic obstructive pulmonary disease, c clinical, nCRT neoadjuvant chemoradiotherapy, ADC adenocarcinoma, SCC squamous cell carcinoma
Surgical outcomes
| Before matching | After matching | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Semiprone ( | Prone ( |
| Semiprone ( | Prone ( |
| |||||
|
|
|
|
| |||||||
| Blood loss (mL) | 320 | (0–1460) | 300 | (100–680) | 0.369 | 388 | (197–547) | 300 | (100–6780) | 0.753 |
| Length of operation (min) | 417 | (318–547) | 235 | (147–336) | < 0.001 | 368 | (50–1460) | 225 | (147–336) | < 0.001 |
| Total lymph node yield | 18 | (5–80) | 13 | (3–33) | 0.001 | 16 | (6–80) | 13 | (3–33) | 0.019* |
| R0 resection | 77 | 94% | 36 | 92% | 0.685 | 36 | 92% | 34 | 92% | 0.946 |
| Conversion (total) | 7 | 9% | 4 | 10% | 0.896 | 2 | 5% | 4 | 10% | 0.395 |
| Conversion (thoracic phase) | 5 | 6% | 1 | 3% | 0.403 | 2 | 5% | 1 | 3% | 0.556 |
Data are expressed as N (%) or median (range)
*P = 0.128 after exclusion of paratracheally resected lymph nodes
Postoperative outcomes
| Before matching | After matching | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Semiprone ( | Prone ( |
| Semiprone ( | Prone ( |
| |||||
|
|
|
|
| |||||||
| In-hospital mortality | 5 | 6% | 2 | 5% | 0.831 | 1 | 3% | 2 | 5% | 0.556 |
| Pneumonia | 30 | 37% | 14 | 36% | 0.941 | 19 | 49% | 14 | 36% | 0.252 |
| Pulmonary embolism | 2 | 2% | 0 | 0% | 0.325 | 1 | 3% | 0 | 0% | 0.314 |
| Anastomotic leakage | 18 | 22% | 14 | 36% | 0.104 | 10 | 26% | 14 | 36% | 0.326 |
| Mediastinitis | 9 | 11% | 6 | 15% | 0.492 | 5 | 13% | 6 | 15% | 0.745 |
| Chylothorax | 30 | 37% | 11 | 28% | 0.363 | 15 | 38% | 11 | 28% | 0.337 |
| Laryngeal nerve palsy/injury | 6 | 7% | 3 | 8% | 0.941 | 4 | 10% | 3 | 8% | 0.692 |
| Wound infection | 3 | 4% | 3 | 8% | 0.339 | 2 | 5% | 3 | 8% | 0.644 |
| Arrhythmia | 14 | 17% | 10 | 26% | 0.269 | 6 | 15% | 10 | 26% | 0.262 |
| Myocardial infarction | 0 | 0% | 0 | 0% | – | 0 | 0% | 0 | 0% | – |
| ICU stay | 1 | (1–35) | 1 | (1–30) | 0.731 | 1 | (1–16) | 1 | (1–30) | 0.732 |
| Hospital stay | 16 | (8–87) | 17 | (7–84) | 0.879 | 18 | (8–87) | 17 | (7–84) | 0.751 |
Data are expressed as N (%) or median (range)